Spondyloarthritiden: Neue Therapiekonzepte

Schlüsselwörter

Spondyloarthritis - Psoriasisarthritis - Leitlinie Therapie

Keywords

Spondyloarthritis - Psoriatic arthritis - guidelines, therapy

• Literatur

• 1 Kiltz U, Sieper J, Kellner H et al. German Society for Rheumatology S3 guidelines on axial spondyloarthritis including Bechterew‘s disease and early forms: 8. 4 Pharmaceutical therapy, 8. 5 Evaluation of therapy success of pharmaceutical measures. Z Rheumatol 2014; 73 (Suppl. 02) 78-96
• 2 Song IH, Hermann KG, Haibel H et al. Prevention of new osteitis on magnetic resonance imaging in patients with early axial spondyloarthritis during 3 years of continuous treatment with etanercept: data of the ESTHER trial. Rheumatol 2015; 54: 257-261
• 3 Dougados M, van der Heijde D, Sieper J et al. Symptomatic efficacy of etanercept and its effects on objective signs of inflammation in early nonradiographic axial spondyloarthritis: a multicenter, randomized, double-blind, placebo-controlled trial. Arthritis Rheumatol 2014; 66: 2091-2102
• 4 Sieper J, van der Heijde D, Dougados M et al. A randomized, double-blind, placebo-controlled, 16-week study of subcutaneous golimumab in patients with active non-radiographic axial spondyloarthritis. Arthritis Rheumatol 2015;
• 5 Mease P, Sieper J, Van den Bosch F et al. Randomized controlled trial of adalimumab in patients with non-psoriatic peripheral spondyloarthritis. Arthritis Rheumatol 2015; 67: 914-923
• 6 Højgaard P, Glintborg B, Hetland ML et al. Association between tobacco smoking and response to tumour necrosis factor α inhibitor treatment in psoriatic arthritis: results from the DANBIO registry. Ann Rheum Dis 2014;
• 7 Gremese E, Bernardi S, Bonazza S et al. Body weight, gender and response to TNF-alpha blockers in axial spondyloarthritis. Rheumatol 2014; 53: 875-881
• 8 Ritchlin C, Rahman P, Kavanaugh A et al. Efficacy and safety of the anti-IL-12/23 p40 monoclonal antibody, ustekinumab, in patients with active psoriatic arthritis despite conventional non-biological and biological anti-tumour necrosis factor therapy: 6-month and 1-year results of the phase 3, multicentre, double-blind, placebo-controlled, randomised PSUMMIT 2 trial. Ann Rheum Dis 2014; 73: 990-999
• 9 Kavanaugh A, Ritchlin C, Rahman P et al. Ustekinumab, an anti-IL-12/23 p40 monoclonal antibody, inhibits radiographic progression in patients with active psoriatic arthritis: results of an integrated analysis of radiographic data from the phase 3, multicentre, randomised, double-blind, placebo-controlled PSUMMIT-1 and PSUMMIT-2 trials. Ann Rheum Dis 2014; 73: 1000-1006
• 10 Kavanaugh A, Mease PJ, Gomez-Reino JJ et al. Longterm (52-week) Results of a Phase III Randomized, Controlled Trial of Apremilast in Patients with Psoriatic Arthritis. J Rheumatol 2015; 42: 479-488
• 11 Jandus C, Bioley G, Rivals JP et al. Increased numbers of circulating polyfunctional Th17 memory cells in patients with seronegative spondylarthritides. Arthritis Rheum 2008; 58: 2307-2317
• 12 Menon B, Gullick NJ, Walter GJ et al. Interleukin-17+CD8+ T cells are enriched in the joints of patients with psoriatic arthritis and correlate with disease activity and joint damage progression. Arthritis Rheumatol 2014; 66: 1272-1281
• 13 Baeten D, Baraliakos X, Braun J et al. Anti-interleukin-17A monoclonal antibody secukinumab in treatment of ankylosing spondylitis: a randomised, double-blind, placebo-controlled trial. Lancet 2013; 382: 1705-1713
• 14 McInnes IB, Sieper J, Braun J et al. Efficacy and safety of secukinumab, a fully human anti-interleukin-17A monoclonal antibody, in patients with moderate-to-severe psoriatic arthritis: a 24-week, randomised, double-blind, placebo-controlled, phase II proof-of-concept trial. Ann Rheum Dis 2014; 73: 349-356
• 15 Mease PJ, Genovese MC, Greenwald MW et al. Brodalumab, an anti-IL17RA monoclonal antibody, in psoriatic arthritis. N Engl J Med 2014; 370: 2295-2306